I 
117TH CONGRESS 
2D SESSION 
H. R. 9310 
To amend the Public Health Service Act to give the United States Preventive 
Services Task Force the authority to take early action based on scientific 
evidence, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
NOVEMBER 16, 2022 
Ms. BLUNT ROCHESTER introduced the following bill; which was referred to 
the Committee on Energy and Commerce 
A BILL 
To amend the Public Health Service Act to give the United 
States Preventive Services Task Force the authority to 
take early action based on scientific evidence, and for 
other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Preventive Services 
Early Action Act’’. 
VerDate Sep 11 2014 
01:55 Nov 22, 2022
Jkt 039200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H9310.IH
H9310
kjohnson on DSK79L0C42PROD with BILLS
SEC. 2. CHANGES TO UNITED STATES PREVENTIVE SERV-
ICES TASK FORCE. 
Section 915(a) of the Public Health Service Act (42 
U.S.C. 299b–4(a)) is amended— 
(1) in paragraph (2)— 
(A) in subparagraph (E), by striking 
‘‘and’’ at the end; 
(B) in subparagraph (F), by striking the 
period at the end and inserting ‘‘; and’’; and 
(C) by adding at the end the following: 
‘‘(G) the publication of quarterly reports 
on the Task Force’s website identifying— 
‘‘(i) a list of clinical preventive rec-
ommendations of the Task Force with re-
spect to the scientific information de-
scribed in paragraph (4)(B); and 
‘‘(ii) a list of topics that the Scientific 
Director determines are appropriate for 
early action as described in paragraph 
(5).’’; 
(2) by redesignating paragraphs (4), (5), (6), 
and (7) as paragraphs (7), (8), (9), and (11), re-
spectively; 
(3) after making such redesignations, by insert-
ing after paragraph (3) the following: 
VerDate Sep 11 2014 
01:55 Nov 22, 2022
Jkt 039200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H9310.IH
H9310
kjohnson on DSK79L0C42PROD with BILLS
‘‘(4) ONGOING
REVIEW
OF
SCIENTIFIC
EVI-
DENCE AND REQUESTS FOR EARLY ACTION.—For 
the purpose described in paragraph (1), the Task 
Force shall establish and implement a process for 
the ongoing review of scientific evidence related to 
updating previous clinical preventive recommenda-
tions of the Task Force under paragraph (5) and re-
viewing new topics for the development of rec-
ommendations for the health care community. Such 
scientific evidence shall include— 
‘‘(A) information from sources audited 
under the LitWatch process described in Ap-
pendix III of the United States Preventive 
Services Task Force Procedure Manual (or any 
successor to such process); and 
‘‘(B) information submitted through a pub-
lic submission process, which may include evi-
dence— 
‘‘(i) of the impact of clinical preven-
tive services on populations or age groups 
for which such clinical preventive services 
do not have in effect a rating of A or B; 
‘‘(ii) to fill research gaps identified by 
the Task Force; 
VerDate Sep 11 2014 
01:55 Nov 22, 2022
Jkt 039200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H9310.IH
H9310
kjohnson on DSK79L0C42PROD with BILLS
‘‘(iii) of a new, novel screening modal-
ity or technology, preventive medication, or 
other preventive service not previously re-
viewed by the Task Force; 
‘‘(iv) of health outcomes from a clin-
ical preventive service that was previously 
considered but not recommended by the 
Task Force; or 
‘‘(v) changes in the public health im-
pact of a specific condition, whether in 
general or as such changes relate to a spe-
cific population. 
‘‘(5) EARLY ACTION BASED ON SCIENTIFIC EVI-
DENCE.— 
‘‘(A) DETERMINATION BY SCIENTIFIC DI-
RECTOR.—Not less than once per quarter, the 
Scientific Director shall determine whether the 
scientific evidence reviewed under paragraph (4) 
supports— 
‘‘(i) early review of a previous clinical 
preventive recommendation of the Task 
Force before the previous recommendation 
is subject to full review under the 5-year 
review period described in paragraph (2); 
or 
VerDate Sep 11 2014 
01:55 Nov 22, 2022
Jkt 039200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H9310.IH
H9310
kjohnson on DSK79L0C42PROD with BILLS
‘‘(ii) modification of a previous clinical 
preventive recommendation of the Task 
Force or any portion thereof before the 
previous recommendation is subject to full 
review under the 5-year review period de-
scribed in paragraph (2). 
‘‘(B) CONSIDERATIONS.—In making a de-
termination under subparagraph (A), the Sci-
entific Director shall take into consideration 
whether the scientific evidence involved— 
‘‘(i) includes information on a new or 
novel intervention, modality, technology, 
population, or strategy not previously con-
sidered by the Task Force in the develop-
ment of the previous clinical preventive 
recommendation; 
‘‘(ii) helps to address a research gap 
identified by the Task Force when devel-
oping the previous recommendation; 
‘‘(iii) relates to a previous rec-
ommendation for a preventive service or 
treatment of a disease or condition with a 
high impact on public health or with dis-
parities in screening rates, incidence, or 
VerDate Sep 11 2014 
01:55 Nov 22, 2022
Jkt 039200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H9310.IH
H9310
kjohnson on DSK79L0C42PROD with BILLS
health outcomes linked to socioeconomic 
status or race; 
‘‘(iv) is based on the development of 
new technologies or modalities that would 
allow for easier disease detection or in-
crease utilization of recommended clinical 
preventative services; or 
‘‘(v) 
is 
supported 
by 
additional 
sources of data for any subpopulations (in-
cluding subpopulations based on gender, 
race, ethnicity, genetic predisposition, so-
cioeconomic status, geographic location, or 
other risk factors) not considered in the 
previous recommendation. 
‘‘(C) RESPONSE BY TASK FORCE.—If the 
Scientific Director of the Task Force deter-
mines under subparagraph (A) that the sci-
entific evidence supports the need for early ac-
tion, the Task Force shall— 
‘‘(i) review the scientific evidence in 
support of the determination at the next 
meeting of the Task Force, which shall be 
held not later than 3 months after the Sci-
entific Director’s determination; and 
‘‘(ii) determine that— 
VerDate Sep 11 2014 
01:55 Nov 22, 2022
Jkt 039200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H9310.IH
H9310
kjohnson on DSK79L0C42PROD with BILLS
‘‘(I) the scientific evidence does 
not support the need for early action; 
‘‘(II) the scientific evidence sup-
ports the need for an early review of 
a previous clinical preventive rec-
ommendation before the previous rec-
ommendation is subject to full review 
under the 5-year review period de-
scribed in paragraph (2); or 
‘‘(III) the scientific evidence sup-
ports the need to modify a previous 
clinical preventive recommendation or 
any portion thereof before the pre-
vious recommendation is subject to 
full review under the 5-year review pe-
riod described in paragraph (2), which 
may include recommending a new 
clinical preventive service, screening 
test, or preventive medication without 
reviewing or modifying the eligible 
population 
in 
the 
previous 
rec-
ommendation. 
‘‘(D) EARLY ACTION.—If the Task Force 
determines that the scientific evidence supports 
the need for an early review of a previous clin-
VerDate Sep 11 2014 
01:55 Nov 22, 2022
Jkt 039200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H9310.IH
H9310
kjohnson on DSK79L0C42PROD with BILLS